ALX Oncology rises as early breast cancer trial shows promise

ALX Oncology Holdings

30/01/2026 13:40

** Shares of drug developer ALX Oncology ALXO.O rise 4.46% to $1.64 premarket

** Co says experimental cancer drug, evorpacept, showed encouraging results in an early-stage trial for patients with advanced breast cancer

** Co says 5 of 9 patients saw tumor shrinkage; treatment worked better in patients with higher CD47 levels, a protein that helps cancer evade the immune system

** Co says median time before cancer worsened was 7.4 months

** Shares down ~32% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))